Myeloid-derived suppressor cells (MDSCs) are potently immunosuppressive innate immune cells that accumulate in advanced cancer patients and actively inhibit anti-tumor T lymphocyte responses [1] . Increased numbers of circulating MDSCs directly correlate with melanoma patient morbidity and reduced anti-tumor immune responses [2, 3] . Previous studies have revealed that monocyte-derived macrophage migration inhibitory factor (MIF) is necessary for the immune suppressive function of MDSCs in mouse models of melanoma [4, 5] . To investigate whether MIF participates in human melanoma-induced MDSC differentiation and/or suppressive function, we have established an in vitro MDSC induction model using primary, normal human monocytes co-cultured with human melanoma cell lines in the presence or absence of the MIF antagonist-4-IPP [4, [6] [7] [8] [9] . To identify potential mechanistic effectors, we have performed transcriptome analyses on cultured monocytes and on melanoma-induced MDSCs obtained from either untreated or 4-IPP-treated A375:monocyte co-cultures. Here, we present a detailed protocol, which can facilitate easy reproduction of the microarray results (NCBI GEO accession number GSE73333) published by Yaddanapudi et al.
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Experimental design, materials, and methods

Monocyte isolation and cell lines
Peripheral blood was collected from healthy donors. Peripheral blood mononuclear cells (PBMCs) were isolated from the peripheral blood by density gradient centrifugation (Ficoll-Hypaque, GE, Piscataway, NJ). 
Contents lists available at ScienceDirect
Genomics Data j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / g d a t a ATCC. A375 cell line was authenticated by ATCC cell bank using the Short Tandem Repeat (STR) profiling.
In vitro generation of human MDSC and MIF-inhibitor treatment
We established an in vitro model of melanoma cell-line-induced MDSCs that faithfully recapitulates patient-derived CD14 + HLADR [10] [11] [12] . Furthermore, in contrast to tumor cell-free cultured monocytes, A375-MDSCs exhibit potent suppressive activity against autologous T cell proliferation and IFN-γ production [9, 10] .
Microarray Analysis
Gene expression profiles of vehicle-treated A375-MDSCs or 4-IPPtreated A375-MDSCs (A375-MDSC + 4-IPP) were compared to that obtained using monocytes cultured without tumor cells (Fig. 1) . Total RNA from cultured monocytes, vehicle-treated, and 4-IPP-treated A375-MDSCs (n = 3) were isolated post-68 h in vitro culture and analyzed over a microarray. For RNA extraction, cells were lysed in buffer RLT (Qiagen, Valencia, CA), homogenized, and purified using RNeasy mini kit (Qiagen) following manufacturer's instructions. Integrity of RNA was checked using a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). Biotinylated cRNA was prepared from 100 ng of total RNA according to the standard protocol for Affymetrix 3′ IVT Express Plus Reagent kit. Following fragmentation, cRNA was hybridized for 16 h at 45°C to Affymetrix Primeview Human arrays according to the GeneChip 3′ Array Hybridization User Manual from Affymetrix. The arrays were processed following the manufacturer recommended wash and stain protocol on an Affymetrix FS-450 fluidics station and scanned on an Affymetrix GeneChip scanner. The resulting .cel files were imported into Partek Genomics Suite 6.6 and transcripts were normalized and summarized using RMA as normalization and background correction method. Contrasts in a 1-way ANOVA were set up to compare the treatments of interest.
Step-up False Discovery Rate was chosen as multiple test correction for the resulting p-values. The microarray datasets discussed in current study have been deposited in NCBI's Gene Expression Omnibus (GEO; www.ncbi.nlm.nih.gov/geo) and are accessible through GEO Series accession number GSE73333.
Conclusions
A microarray analysis of normal monocytes, vehicle-treated-A375-MDSCs, and 4-IPP-treated A375-MDSCs was performed to identify downstream MIF effectors that could be responsible for MIF-dependent phenotypic and functional contributions to human MDSCs. Melanoma cell line-induced MDSC transcriptome reveals a unique gene expression profile that is largely reversed to normal monocyte levels by MIF inhibition. Inflammatory cytokines, chemokines/chemokine receptors, matrix metalloproteases, angiogenic growth factors, and arachidonic acid/ prostaglandin-generating enzymes are all differentially expressed in A375-MDSCs and restored to "normal" levels by MIF inhibition. These results are discussed in detail in the article published by Yaddanapudi et al. (2015) in Cancer Immunology Research [10] .
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